Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Multiple sclerosis-related fatigue and possibilities of its correction

https://doi.org/10.14412/2074-2711-2016-1-82-85

Full Text:

Abstract

Multiple sclerosis (MS)-related fatigue is encountered in 75–92% of patients and it is one of the key symptoms that affect quality of life. Physicians and patients' relatives frequently underestimate MS-related fatigue; the latter may occur at any disease stage, its degree is inadequate to physical exercise and reduces after a short-term daytime rest. Fatigue due to MS is not directly related to the degree of paresis; however, it is more common in patients with pyramidal insufficiency. Overfatigue may be the first symptom of an MS exacerbation. The genesis of fatigue in MS is not known with certainty. The development of this symptom is associated with impairments in neuroimmune responses and biochemical processes and with the administration of some drugs. Special tests and scales are used to objectify the degree of fatigue. The most commonly used questionnaires are the Fatigue Severity Scores to rate physical and mental fatigue, as well as the Modified Fatigue Impact Scale in patients having MS. When a patient with MS complains about fatigue, it is necessary to rule out its other possible causes and to specify its relation to MS and the necessity of fatigue correction. Аmantadine is one of the drugs used for the symptomatic therapy of MS. This paper presents the data of randomized clinical trials evaluating the efficacy and safety of this drug for the symptomatic treatment of MS. Correction of MS-related fatigue requires a multidisciplinary approach that involves a combination of drug therapy, therapeutic exercises, active lifestyle, and relatives' understanding.

About the Authors

N. Yu. Lashch
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia 1, Ostrovityanov St., Moscow 117997
Russian Federation
Department of Neurology, Neurosurgery, and Medical Genetics


A. N. Boiko
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia 1, Ostrovityanov St., Moscow 117997
Russian Federation
Department of Neurology, Neurosurgery, and Medical Genetics


References

1. Гусева ЕИ, Завалишин ИА, Бойко АН, редакторы. Рассеянный склероз. Москва: Реал Тайм; 2011. 528 с. [Guseva EI, Zavalishin IA, Boiko AN, editors. Rasseyannyi skleroz [Multiple sclerosis]. Moscow: Real Taim; 2011. 528 p.]

2. Шмидт ТЕ, Яхно НН. Рассеянный склероз: руководство для врачей. 2-е изд. Москва: МЕДпресс-информ; 2010. 272 с. [Shmidt TE, Yakhno NN. Rasseyannyi skleroz: rukovodstvo dlya vrachei [Multiple sclerosis: a guide for physicians]. 2nd ed. Moscow: MEDpress-inform; 2010. 272 p.]

3. Filippi M, Rocca M, Colombo D, et al. Functional magnetic resonance imaging correlates of fatique in multiple sclerosis. Neuroimage. 2002 Mar;15(3):559-67.

4. Heesen C, Nawrath L, Reich C, et al. Fatique in multiple sclerosis: an example of cytokine mediated sickness behavior. J Neurol Neurosurg Psychiatry. 2006 Jan;77(1):34-9.

5. Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatique in multiple sclerosis; a two centre phase 2 study. J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):179-83.

6. Payne C, Wiffen PJ, Martin S. Interventions for fatigue and weight loss in adults with advanced progressive illness. Cochrane Database Syst Rev. 2012 Jan 18;1:CD008427. doi: 10.1002/14651858.CD008427.pub2.

7. Shaygannejad V, Janghorbani M, Ashtari F, Zakeri H. Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: A randomized, blinded, crossover study. Neurol Res. 2012 Nov;34(9):854-8. doi: 10.1179/1743132812Y. 0000000081. Epub 2012 Sep 12.

8. Ledinek AH, Sajko MC, Rot U. Evaluating the effects of amantadine, modafi nil and acetyl-L-carnitine on fatigue in multiple sclerosis – result of a pilot randomized, blind study. Clin Neurol Neurosurg. 2013 Dec;115 Suppl 1:S86-9. doi: 10.1016/j.clineuro. 2013.09.029.

9. Pucci E, Branаs P, D'Amico R, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002818.

10. Henze T, Rieckmann P, Toyka KV. Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006;56(2):78-105. Epub 2006 Sep 8.

11. Induruwa I, Constantinescu CS, Gran B. Fatigue in multiple sclerosis – a brief review. J Neurol Sci. 2012 Dec 15;323(1-2):9-15. doi: 10.1016/j.jns.2012.08.007. Epub 2012 Aug 27.

12. Generali JA, Cada DJ. Off-Label Drug Uses Amantadine: Multiple Sclerosis-Related Fatigue. Hosp Pharm. 2014 Sep;49(8):710-2. doi: 10.1310/hpj4908-710.

13. Карабань ИН. Применение блокатора глутаматных рецепторов амантадина в неврологии. Международный неврологический журнал. 2012;(2):143-9. [Karaban' IN. The use of blockers of glutamate receptors amantadine in neurology. Mezhdunarodnyi nevrologicheskii zhurnal. 2012;(2):143-9. (In Russ.)].

14. Crosby NJ, Deane KH, Clarke CE. Amantadine in Parkinson's disease (Review). Cochrane Database Syst Rev. 2003;(2):CD003467.


For citation:


Lashch N.Yu., Boiko A.N. Multiple sclerosis-related fatigue and possibilities of its correction. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(1):82-85. (In Russ.) https://doi.org/10.14412/2074-2711-2016-1-82-85

Views: 2187


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)